Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Cox

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
Breast Cancer Research : BCR|September 22, 2006
A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)David G Cox, Hélène Blanché, Celeste L Pearce, et al.
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Plos One|March 5, 2011
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)Daniele Campa, Anika Hüsing, Angelika Stein, et al.
Breast Cancer Research : BCR|August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesElsa Curtit, Xavier Pivot, Julie Henriques, et al.
International Journal of Cancer|October 16, 2007
Haplotypes of the estrogen receptor beta gene and breast cancer risk, David G Cox, Philip Bretsky, et al.
Plos One|July 4, 2008
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)Alpa V Patel, Iona Cheng, Federico Canzian, et al.
Cancer Research|April 6, 2007
A common 8q24 variant in prostate and breast cancer from a large nested case-control studyFredrick R Schumacher, Heather Spencer Feigelson, David G Cox, et al.
Cancer Research|February 21, 2006
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studiesHeather Spencer Feigelson, David G Cox, Howard M Cann, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 7, 2009
Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort ConsortiumJames D McKay, Marjorie L McCullough, Regina G Ziegler, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
Breast Cancer Research : BCR|September 22, 2006
A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)David G Cox, Hélène Blanché, Celeste L Pearce, et al.
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Plos One|March 5, 2011
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)Daniele Campa, Anika Hüsing, Angelika Stein, et al.
Breast Cancer Research : BCR|August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesElsa Curtit, Xavier Pivot, Julie Henriques, et al.
International Journal of Cancer|October 16, 2007
Haplotypes of the estrogen receptor beta gene and breast cancer risk, David G Cox, Philip Bretsky, et al.
Plos One|July 4, 2008
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)Alpa V Patel, Iona Cheng, Federico Canzian, et al.
Cancer Research|April 6, 2007
A common 8q24 variant in prostate and breast cancer from a large nested case-control studyFredrick R Schumacher, Heather Spencer Feigelson, David G Cox, et al.
Cancer Research|February 21, 2006
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studiesHeather Spencer Feigelson, David G Cox, Howard M Cann, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 7, 2009
Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort ConsortiumJames D McKay, Marjorie L McCullough, Regina G Ziegler, et al.
Pageof 11